PacBio Q2 revenue $39M, net loss $44.7M; CEO Henry steps down, Van Oene appointed; restructuring cuts 8% workforce

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Q2 revenue $39.0M (down 2% YoY); GAAP net loss $44.7M ($0.14 loss per share); non-GAAP net loss $41.9M.
Revio placements 20, Vega placements 26; consumable revenue $20.1M; annualized Revio pull-through ~$202K.
Full-year 2026 revenue guidance $155-165M; commenced SPRQ-Nx chemistry rollout at $345/genome.
CEO Christian Henry steps down effective Aug 5; COO Mark Van Oene appointed President and CEO; Henry stays as advisor through Dec 2026.
Restructuring plan cuts ~40 employees (8% workforce); expects $30-40M annualized OpEx reduction by end 2027; $2M pre-tax charges in Q3.

item 2.02 item 2.05 item 5.02 item 7.01 item 9.01

Featured in Daily 8-K Digest

Selected #9 for 2026-08-05. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.